CAMBRIDGE, Mass. and NEW YORK--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the Phase 3 clinical trial of oral AP23573, its novel mTOR inhibitor, will be conducted in patients with metastatic soft-tissue and bone sarcomas by the Sarcoma Alliance for Research through Collaboration (SARC) in cooperation with the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of Cancer (EORTC).
